{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-22-000083","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.761260+00:00","generated_at":"2026-06-25T22:20:28.104212+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Castle Biosciences Q1 revenue up 18% to $26.9M; net loss widens to $24.6M; raises 2022 guidance","bullets":["Revenue $26.9M (+18% YoY); adjusted revenue $26.3M (+50% YoY); net loss ($24.6M) vs ($4.3M) prior year.","Total test reports 8,627 (+68% YoY); DecisionDx-Melanoma +48%, DecisionDx-SCC +117%.","2022 total revenue guidance raised to $118-123M from $115-120M.","Acquired AltheaDx/IDgenetix PGx test for mental health in April 2022; adds ~$5B TAM.","Operating cash flow ($21.4M) vs ($3.6M); adjusted EBITDA ($11.4M) vs $0.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-22-000083","json":"https://secwatch.observer/filing/0001447362-22-000083.json","markdown":"https://secwatch.observer/filing/0001447362-22-000083.md","text":"https://secwatch.observer/filing/0001447362-22-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000083/0001447362-22-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000083/cstl-20220509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:20:28.104212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}